NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: TransCode Therapeutics' TTX-MC138 Preclinical Data for Glioblastoma Treatment
TL;DR
TransCode Therapeutics' TTX-MC138 offers a potential edge in treating aggressive glioblastoma, with preclinical success suggesting future clinical and market advantages.
Systemic delivery of TTX-MC138 reached brain tumors in models, increased apoptosis, and improved survival, supporting its advancement toward clinical trials.
This research brings hope for better glioblastoma treatments, potentially improving survival and quality of life for patients with this aggressive cancer.
TransCode's RNA therapy targets a metastasis biomarker, showing promise against brain cancer in a study published in the Journal of Functional Biomaterials.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics published peer-reviewed preclinical research supporting the use of its lead candidate TTX-MC138 for treating glioblastoma multiforme, one of the most aggressive forms of brain cancer.
TransCode Therapeutics (NASDAQ: RNAZ) is a clinical stage company pioneering immunoncology and RNA therapeutic treatments for high risk and advanced cancers, with TTX-MC138 as its lead therapeutic candidate.
The study demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in orthotopic glioblastoma models, significantly increased tumor cell apoptosis, and resulted in a statistically significant improvement in survival.
The research was published in the Journal of Functional Biomaterials and was conducted in collaboration with Michigan State University.
TTX-MC138 is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis, and is now being studied for glioblastoma treatment.
The findings support the potential advancement of TTX-MC138 into future clinical evaluation for patients with glioblastoma, building on completed IND-enabling studies and existing Phase 1 clinical experience outside the central nervous system.
The findings further validate TransCode's TTX delivery platform for delivering therapeutic agents to difficult-to-reach areas like brain tumors.
The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
BioMedWire is a specialized communications platform focusing on Biotechnology, Biomedical Sciences and Life Sciences sectors that published this announcement as part of its distribution services.
The full press release can be viewed at https://ibn.fm/XdHxZ.
Curated from InvestorBrandNetwork (IBN)
